February 12th 2025
Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable to complete surgical resection are indicated in the approval.
Bruce Feinberg, DO; Kathy Oubre, Michael Reff, RPh, MBA; Jamile M. Shammo, MD; and Ruben Mesa, MD, discuss the incorporation of quality care programs for improved disease management and patient care for MPNs.
FDA Approves Symdeko to Treat the Underlying Cause of Cystic Fibrosis
Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000
FDA Approves First Radioactive Drug for Rare Type of GI Cancer
Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies
Diagnosing and Treating Neutropenia: Q&A With Dr Daniel J. DeAngelo